TScan Therapeutics, Inc. (TCRX) - Form 8-K Summary
Business Context and Reporting Period
TScan Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on March 4, 2026. The filing announces the release of financial results for the fourth quarter and the full fiscal year ended December 31, 2025. The company is classified as an emerging growth company.
Key Financial Metrics
This Form 8-K serves as a notification of the press release (Exhibit 99.1) containing the financial results. The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these details.
Material Changes
The filing does not contain specific data regarding material changes versus prior periods. It solely references the issuance of the Q4 and full-year 2025 results announcement.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in this report and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. It will not be incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed within the text of this 8-K form.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and FY 2025 financial figures.
- Verify the company's cash runway and burn rate given its status as an emerging growth company.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the trading status of TCRX on The Nasdaq Global Market.